Leading the charge in cancer care
DDW Editor Reece Armstrong speaks to Michael Metzger, CEO of… Read More
DDW Editor Reece Armstrong speaks to Michael Metzger, CEO of… Read More
The US Food and Drug Administration (FDA) has approved axatilimab-csfr (Niktimvo), a colony stimulating factor-1 receptor-blocking antibody, for the treatment of chronic graft-versus-host disease (cGVHD). It is approved for use after the failure of at least two prior lines of systemic therapy in adult and paediatric… Read More